Immediate Termination of Study by CRO or Pfizer Sample Clauses

Immediate Termination of Study by CRO or Pfizer. CRO or Pfizer may terminate the Study immediately upon written notice to Institution for causes that include failure to enroll Study Subjects at a rate sufficient to achieve Study performance goals; material unauthorize d deviations from the Protocol or reporting requirement (2) Okamžité ukončení Studie ze strany CRO nebo společnosti Pfizer. CRO nebo společnost Pfizer může Studii ukončit s okamžitou účinností na základě písemného oznámení podaného Instituci z důvodů, mezi které patří nezařazení dostatečného počtu účastníků pro dosažení cílů Studie; podstatné neoprávněné odchylky od Protokolu s; circumstanc es that in CRO’s or Pfizer’s opinion pose risks to the health or well-being of Study Subjects; regulatory authority actions relating to the Study or the Investigatio nal Drug; any non- compliance by the Institution with local laws, ICH GCP, or the terms of Section 20 (Anti- Corruption) of this Agreement; or non- compliance by the Principal Investigator with the comparable terms of the agreement between CRO and Principal Investigator. nebo od požadavků na podávání zpráv; okolnosti, které podle názoru CRO nebo společnosti Pfizer představují riziko pro zdraví nebo blaho subjektů Studie; kroky kontrolních úřadů v souvislosti se Studií nebo hodnoceným léčivem; jakékoli nedodržení místních zákonů, pokynů ICH GCP nebo podmínek článku 20 této Smlouvy (Protikorupční opatření) ze strany Instituce; nebo nedodržení srovnatelných podmínek smlouvy mezi CRO a Hlavním zkoušejícím ze strany Hlavního zkoušejícího. (3)
Sample 1See All (7)
AutoNDA by SimpleDocs
Immediate Termination of Study by CRO or Pfizer. CRO or Pfizer may terminate the Study immediately upon written notice to Institution and Principal (2) Okamžité ukončení studie ze strany CRO nebo společnosti Pfizer. CRO nebo společnost Pfizer mohou studii okamžitě ukončit na základě písemného oznámení zdravotnickému Investigator for causes that include failure to enroll Study Subjects at a rate sufficient to achieve Study performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in CRO’s or Xxxxxx’x opinion pose risks to the health or well- being of Study Subjects; or regulatory agency actions relating to the Study or the Pfizer Product, or any non- compliance by the Institution and/or Principal Investigator with local laws or the terms of Section 20 (Anti- Corruption) of this Agreement. zařízení a hlavnímu zkoušejícímu, a to z důvodů, mezi něž patří zařazování pacientů do studie tempem, které není dostatečné k dosažení cílů provádění studie, neschválené podstatné odchylky od protokolu nebo požadavků na hlášení, okolnosti, které podle názoru CRO nebo společnosti Pfizer představují riziko pro zdraví nebo pocit pohody pacientů ve studii, nebo opatření regulačních orgánů týkající se studie nebo přípravku společnosti Pfizer, případně nedodržování místních zákonů nebo podmínek v odstavci 20 (Protikorupční zásady) této smlouvy ze strany zdravotnického zařízení a hlavního zkoušejícího.
Sample 1
Immediate Termination of Study by CRO or Pfizer. CRO or Pfizer may terminate the Study immediately upon written notice to Institution for causes that include failure to enroll Study Subjects at a rate sufficient to achieve Study performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in CRO’s or Pfizer’s opinion pose risks to the health or well-being of Study Subjects; regulatory authority actions relating to the Study or the Investigational Drug; termination of the associated agreement between CRO and Principal Investigator (see Section 1.3, Agreement between CRO and Principal Investigator): any non-compliance by the Institution with local laws, ICH GCP, or the terms of Section 20 (Anti- Corruption) of this Agreement; or non- compliance by the Principal Investigator with the comparable terms of the agreement between CRO and Principal Investigator.
Sample 1
Immediate Termination of Study by CRO or Pfizer. CRO or Pfizer may terminate the Study immediately upon written notice to Institution for causes that include failure to enroll Study Subjects at a rate sufficient to achieve Study performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in CRO’s or Xxxxxx’x opinion pose risks to the health or well- being of Study Subjects; regulatory authority actions relating to the hlavným skúšajúcim podobných ustanovení zmluvy medzi CRO a hlavným skúšajúcim.
Sample 1

Related to Immediate Termination of Study by CRO or Pfizer

  • Immediate Termination A party has the right to immediately terminate this agreement by notice in writing to the other party upon the occurrence of any of the following events:

  • Termination of Agreement for Cause 5.1.1. If A/E breaches any of the covenants or conditions of this AGREEMENT, COUNTY shall have the right to terminate this AGREEMENT upon ten (10) days written notice prior to the effective day of termination.

  • Termination of Benefits Except as provided in Section 2 above or as may be required by law, Executive’s participation in all employee benefit (pension and welfare) and compensation plans of the Company shall cease as of the Termination Date. Nothing contained herein shall limit or otherwise impair Executive’s right to receive pension or similar benefit payments that are vested as of the Termination Date under any applicable tax-qualified pension or other plans, pursuant to the terms of the applicable plan.

  • Complete Disposal Upon Termination of Service Agreement Upon Termination of the Service Agreement Provider shall dispose or delete all Student Data obtained under the Service Agreement. Prior to disposition of the data, Provider shall notify LEA in writing of its option to transfer data to a separate account, pursuant to Article II, section 3, above. In no event shall Provider dispose of data pursuant to this provision unless and until Provider has received affirmative written confirmation from LEA that data will not be transferred to a separate account.

  • Transition of Registry upon Termination of Agreement Upon expiration of the Term pursuant to Section 4.1 or Section 4.2 or any termination of this Agreement pursuant to Section 4.3 or Section 4.4, Registry Operator shall provide ICANN or any successor registry operator that may be designated by ICANN for the TLD in accordance with this Section 4.5 with all data (including the data escrowed in accordance with Section 2.3) regarding operations of the registry for the TLD necessary to maintain operations and registry functions that may be reasonably requested by ICANN or such successor registry operator. After consultation with Registry Operator, ICANN shall determine whether or not to transition operation of the TLD to a successor registry operator in its sole discretion and in conformance with the Registry Transition Process; provided, however, that (i) ICANN will take into consideration any intellectual property rights of Registry Operator (as communicated to ICANN by Registry Operator) in determining whether to transition operation of the TLD to a successor registry operator and (ii) if Registry Operator demonstrates to ICANN’s reasonable satisfaction that (A) all domain name registrations in the TLD are registered to, and maintained by, Registry Operator or its Affiliates for their exclusive use, (B) Registry Operator does not sell, distribute or transfer control or use of any registrations in the TLD to any third party that is not an Affiliate of Registry Operator, and (C) transitioning operation of the TLD is not necessary to protect the public interest, then ICANN may not transition operation of the TLD to a successor registry operator upon the expiration or termination of this Agreement without the consent of Registry Operator (which shall not be unreasonably withheld, conditioned or delayed). For the avoidance of doubt, the foregoing sentence shall not prohibit ICANN from delegating the TLD pursuant to a future application process for the delegation of top-­‐level domains, subject to any processes and objection procedures instituted by ICANN in connection with such application process intended to protect the rights of third parties. Registry Operator agrees that ICANN may make any changes it deems necessary to the IANA database for DNS and WHOIS records with respect to the TLD in the event of a transition of the TLD pursuant to this Section 4.5. In addition, ICANN or its designee shall retain and may enforce its rights under the Continued Operations Instrument for the maintenance and operation of the TLD, regardless of the reason for termination or expiration of this Agreement.

  • Termination of Services by the HSP (a) Except as provided in section 11.2(b) and (c) below, the HSP may terminate this Agreement at any time, for any reason, upon giving the Funder at least six months’ Notice.

  • DETERMINATION OF BREACH AND TERMINATION OF AGREEMENT A. Prior to making a determination that the Applicant has failed to comply in any material respect with the terms of this Agreement or to meet any material obligation under this Agreement, the District shall provide the Applicant with a written notice of the facts which it believes have caused the breach of this Agreement, and if cure is possible, the cure proposed by the District. After receipt of the notice, the Applicant shall be given ninety (90) days to present any facts or arguments to the Board of Trustees showing that it is not in breach of its obligations under this Agreement, or that it has cured or undertaken to cure any such breach.

  • Termination of Use These terms and Your access to Our Website may be terminated by Us (at Our sole discretion) at any time without notice or any requirement to give You a reason why. In the event of termination under this clause We shall have no liability to You whatsoever (including for any consequential or direct loss You may suffer).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!